Leading Anti-Cancer Drugs and Associated Market 2012-2022
NEW YORK, April 2, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Leading Anti-Cancer Drugs and Associated Market 2012-2022
Report Details
Cancer treatments - discover which products have greatest potential
Where are cancer-treating drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.
This study investigates leading drugs to treat human cancers. It lets you assess potential sales trends at world market, therapeutic submarket, product and national level to 2022.
How will 25 leading products - including Avastin, Rituxan, Herceptin and Glivec/Gleevec - perform from 2012? See potential revenues and other information. The study also assesses eight recently approved drugs.
Our investigation gives you business research and analysis with sales forecasts. You also see forecasting of five submarkets to 2022, finding potential revenues:
• Traditional antineoplastic agents
• Novel antineoplastic agents
• Hormone therapies
• Immunotherapies
• Other agents.
Find coverage of oncology R&D too, assessing trends and outlooks there.
What does the future hold? The pharma industry has great potential for improving products and increasing revenues from cancer treatments. R&D pipelines in oncology are strong.
There are many promising developments in biopharma, including antibody-drug conjugates and bispecific monoclonal antibodies. The therapeutic and commercial importance of anti-cancer agents will increase from 2012 to 2022, our analysis finds.
What about leading companies? Our work discusses Roche, Novartis, AstraZeneca, Eli Lilly, Celgene and other pharmaceutical companies, evaluating prospects of the industry and market.
Commercial opportunities for cancer treatment remain, with high revenues likely from many drugs - small-molecule products and biological agents (biologicals) - to 2022.
You can investigate the future of cancer treatment now, discovering potential revenues and other trends. Our report shows and explains.
Revenue forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussion of R&D activities. You receive 146 tables and charts and three research interviews.
Nine ways Leading Anti-Cancer Drugs and Associated Market 2012-2022 helps you
In particular, the study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover revenue forecasts to 2022 for 26 prominent drugs
• View prospects for emerging products, seeing their potential
• See market forecasting to 2022 for the US, Japan, the UK, Germany, France, Spain, Italy (EU5),Brazil, Russia, India and China (BRIC)
• Assess leading companies, discovering activities and outlooks
• Review R&D for a range of applications, seeing pipeline trends
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey, receiving detailed interviews.
There, you find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains.
We keep you informed about commercial trends and prospects, helping you to stay ahead.
Gain business research and analysis now for cancer treatments
Our study is for everybody needing industry and market analyses for anti-cancer drugs. You find data, trends and answers there. Please order that report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents
1. Executive Summary
1.1 Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of the Report
2. Introduction
2.1 The Physiology of Cancer
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness and Metastasis
2.1.4 Causes of Cancer
2.2 The Incidence and Prevalence of Cancer
2.2.1 Incidence
2.2.2 Mortality
2.2.3 Survival
2.2.3.1 The Developed World
2.2.3.2 The Developing World
2.3 Treating Tumours
2.3.1 Chemotherapy
2.3.2 Traditional Antineoplastics
2.3.3 Novel Antineoplastics
2.3.3.1 Kinase Receptor Antagonists
2.3.3.2 Other Novel Antineoplastics
2.3.4 Hormone Therapies
2.3.5 Active Immunotherapy
2.3.6 Immunotherapy: Monoclonal Antibodies
3. World Anti-Cancer Drug Market, 2012-2022
3.1 Global Anti-Cancer Drugs Market, 2010
3.2 Global Anti-Cancer Drugs Market Forecast, 2012-2022
3.3 Traditional Antineoplastics Market Forecast, 2012-2022
3.4 Novel Antineoplastics Market Forecast, 2012-2022
3.5 Hormone Therapy Market Forecast, 2012-2022
3.6 Immunotherapy Market Forecast, 2012-2022
4. Leading National Markets, 2012-2022
4.1 Anti-Cancer Drugs - Leading National Markets, 2010
4.2 The US Anti-Cancer Drug Market, 2012-2022
4.3 The Japanese Anti-Cancer Drug Market, 2012-2022
4.4 The Leading Five Anti-Cancer Drug Markets in the EU (EU5), 2012-2022
4.5 Anti-Cancer Drug Markets in BRIC Countries, 2012-2022
4.5.1 Brazil, 2012-2022
4.5.2 Russia, 2012-2022
4.5.3 India, 2012-2022
4.5.4 China, 2012-2022
5. Top 25 Anti-Cancer Drugs: Market Prospects, 2012-2022
5.1 Avastin (Roche)
5.1.1 Avastin Sales, 2010
5.1.2 Avastin Sales Forecast, 2012-2022
5.1.3 Competition for Avastin
5.1.3.1 Rituxan Overtakes Avastin as the Top-Selling Anti-Cancer Drug in 2011
5.2 Rituxan (Roche)
5.2.1 Rituxan Sales, 2010
5.2.2 Rituxan Sales Forecast, 2012-2022
5.2.3 Competition for Rituxan
5.3 Herceptin (Roche)
5.3.1 Herceptin Sales, 2010
5.3.2 Herceptin Sales Forecast, 2012-2022
5.4 Glivec/Gleevec (Novartis)
5.4.1 Glivec/Gleevec Sales, 2010
5.4.2 Glivec/Gleevec Sales Forecast, 2012-2022
5.4.3 Tasigna - The Main Competitor
5.5 Taxotere (Sanofi)
5.5.1 Taxotere Sales, 2010
5.5.2 Taxotere Sales Forecast, 2012-2022
5.5.3 Competition for Taxotere
5.6 Revlimid (Celgene)
5.6.1 Revlimid Sales, 2010
5.6.2 Revlimid Sales Forecast, 2012-2022
5.6.3 Competition for Revlimid
5.7 Alimta (Eli Lilly)
5.7.1 Alimta Sales, 2010
5.7.2 Alimta Sales Forecast, 2012-2022
5.7.3 Competition for Alimta
5.8 Velcade (Takeda/J&J)
5.8.1 Velcade Sales, 2010
5.8.2 Velcade Sales Forecast, 2012-2022
5.8.3 Competition for Velcade
5.9 Erbitux (Bristol-Myers Squibb/Merck/Eli Lilly)
5.9.1 Erbitux Sales, 2010
5.9.2 Erbitux Sales Forecast, 2012-2022
5.9.3 Competition for Erbitux
5.10 Leuplin/Enantone (Takeda/Abbott)
5.10.1 Leuplin/Enantone Sales, 2010
5.10.2 Leuplin/Enantone Sales Forecast, 2012-2022
5.11 Arimidex (AstraZeneca)
5.11.1 Arimidex Sales, 2010
5.11.2 Arimidex Sales Forecast, 2012-2022
5.12 Zometa (Novartis)
5.12.1 Zometa Sales, 2010
5.12.2 Zometa Sales Forecast, 2012-2022
5.13 Xeloda (Roche)
5.13.1 Xeloda Sales, 2010
5.13.2 Xeloda Sales Forecast, 2012-2022
5.14 Tarceva (Roche)
5.14.1 Tarceva Sales, 2010
5.14.2 Tarceva Sales Forecast, 2012-2022
5.15 Femara (Novartis)
5.15.1 Femara Sales, 2010
5.15.2 Femara Sales Forecast, 2012-2022
5.16 Sandostatin (Novartis)
5.16.1 Sandostatin Sales, 2010
5.16.2 Sandostatin Sales Forecast, 2012-2022
5.17 Gemzar (Eli Lilly)
5.17.1 Gemzar Sales, 2010
5.17.2 Gemzar Sales Forecast, 2012-2022
5.18 Zoladex (AstraZeneca)
5.18.1 Zoladex Sales, 2010
5.18.2 Zoladex Sales Forecast, 2012-2022
5.19 Sutent (Pfizer)
5.19.1 Sutent Sales, 2010
5.19.2 Sutent Sales Forecast, 2012-2022
5.20 Temodar (Merck & Co.)
5.20.1 Temodar Sales, 2010
5.20.2 Temodar Sales Forecast, 2012-2022
5.21 Nexavar (Bayer/Onyx)
5.21.1 Nexavar Sales, 2010
5.21.2 Nexavar Sales Forecast, 2012-2022
5.22 Casodex (AstraZeneca)
5.22.1 Casodex Sales, 2010
5.22.2 Casodex Sales Forecast, 2012-2022
5.23 Sprycel (Bristol-Myers Squibb/Otsuka)
5.23.1 Sprycel Sales, 2010
5.23.2 Sprycel Sales Forecast, 2012-2022
5.24 Eloxatin (Sanofi)
5.24.1 Eloxatin Sales, 2010
5.24.2 Eloxatin Sales Forecast, 2012-2022
5.25 Vidaza (Celgene)
5.25.1 Vidaza Sales, 2010
5.25.2 Vidaza Sales Forecast, 2012-2022
6. New Drugs: Market Potential Analysis
6.1 Tasigna (Novartis)
6.1.1 Market Potential
6.2 Afinitor (Novartis)
6.2.1 Market Potential
6.3 Yervoy (Bristol-Myers Squibb)
6.3.1 Market Potential
6.4 Zelboraf (Roche/Daiichi Sankyo)
6.4.1 Market Potential
6.5 Xalkori (Pfizer)
6.5.1 Market Potential
6.6 Halaven (Eisai)
6.6.1 Market Potential
6.7 Zytiga (Johnson & Johnson)
6.7.1 Market Potential
6.8 Vandetanib (AstraZeneca)
6.8.1 Market Potential
7. Leading Companies
7.1 Anti-Cancer Drug Market Dominated by Six Companies
7.2 Roche - Market Leader
7.2.1 Financial Performance, 1H2011
7.2.2 Oncology Pipeline
7.2.3 Future Directions in Cancer Treatment
7.3 Novartis
7.3.1 Financial Performance, 2011
7.3.2 Oncology Pipeline
7.3.3 Future Directions in Cancer Treatment
7.4 AstraZeneca
7.4.1 Financial Performance, Q1-Q3 2011
7.4.2 Oncology Pipeline
7.4.3 Future Directions in Cancer Treatment
7.5 Celgene
7.5.1 Financial Performance, Q1-Q3 2011
7.5.2 Oncology Pipeline
7.5.3 Future Directions in Cancer Treatment
7.6 Eli Lilly
7.6.1 Financial Performance, Q1-Q3 2011
7.6.2 Oncology Pipeline
7.6.3 Future Directions in Cancer Treatment
7.7 Sanofi
7.7.1 Financial Performance, 1H 2011
7.7.2 Oncology Pipeline
7.7.3 Future Directions in Cancer Treatment
8. R&D Pipeline Analysis
8.1 Bladder Cancer Drugs Under Development
8.1.1 Urocidin (Endo Pharmaceuticals/Bioniche Life Sciences)
8.2 Brain Cancer Drugs Under Development
8.2.1 Cilengitide (EMD Serono/Merck)
8.3 Breast Cancer Drugs Under Development
8.3.1 Iniparib (BiPar Sciences/Sanofi)
8.4 Cervical Cancer Drugs Under Development
8.4.1 V503 (Merck & Co.)
8.5 Colorectal Cancer Drugs Under Development
8.5.1 Regarofenib (Bayer HealthCare)
8.6 Kidney Cancer Drugs Under Development
8.6.1 AV-951 (AVEO Pharmaceuticals)
8.7 Leukaemia Drugs Under Development
8.7.1 Bosutinib (Pfizer)
8.8 Liver Cancer Drugs Under Development
8.8.1 Brivanib (Bristol-Myers Squibb)
8.9 Lung Cancer Drugs Under Development
8.9.1 BIBW 2292 (Boehringer Ingelheim)
8.10 Lymphoma Drugs Under Development
8.10.1 SGN-35 (Millennium Pharmaceuticals/Seattle Genetics)
8.11 Multiple Myeloma Drugs Under Development
8.11.1 Carfilzomib (Onyx Pharmaceuticals)
8.12 Ovarian Cancer Drugs Under Development
8.12.1 AMG 386 (Amgen)
8.13 Pancreatic Cancer Drugs Under Development
8.13.1 AMG 479 (Amgen)
8.14 Prostate Cancer Drugs Under Development
8.14.1 MDV-3100 (Astellas Pharma US/Medivation)
8.15 Sarcoma Drugs Under Development
8.15.1 Mifamurtide (Millennium Pharmaceuticals)
8.16 Skin Cancer Drugs Under Development
8.16.1 MAGE-3 (GlaxoSmithKline)
8.17 Solid Tumour Drugs Under Development
8.17.1 AC480 (Ambit Biosciences)
8.18 Stomach Cancer Drugs Under Development
8.18.1 Ramucirumab (Eli Lilly/ImClone Systems)
8.19 Other Cancer Drugs Under Development
8.19.1 Lenvatinib (Eisai)
9. SWOT and STEP Analysis
9.1 Strengths
9.1.1 High Profile Nature of Cancer
9.1.2 Off-Label Prescriptions are Common
9.1.3 Strong Drug Development Incentives
9.2 Weaknesses
9.2.1 Tumour Resistance
9.2.2 Pricing-Out the Developing World?
9.3 Opportunities
9.3.1 Rising Incidence of Cancer
9.3.1.1 Ageing Populations
9.3.1.2 Smoking
9.3.1.3 Obesity
9.3.1.4 The Developing World
9.3.2 Personalised Medicine
9.3.3 Live Licensing
9.3.4 Convenient Drugs
9.4 Threats
9.4.1 The Cost-Effectiveness Debate
9.4.2 Governments: Leading Payers for Drugs
9.4.3 Efficacy, Toxicity and Alternative Treatments
9.5 Biosimilars and Generics: Opportunity or Threat?
9.6 Personalised Medicine
9.6.1 Cancer Heterogeneity
9.6.2 Pharmacogenomics
9.6.3 Genome Screening
9.6.4 Biomarkers and Diagnostics
9.6.5 Theranostics
10. Research Interviews
10.1 Interview with Dr Kent C. Osborne, Baylor College of Medicine
10.1.1 On Challenges in Developing Anti-Cancer Therapies
10.1.2 On Major Areas of Focus
10.1.3 On Cancer Vaccines
10.1.4 On Areas with Potential for Increased Revenue Generation
10.1.5 On R&D Pipeline
10.1.6 On Difficulties Conducting Clinical Trials
10.2 Interview with Dr Jason Kantor, Director, RBC Capital Markets
10.2.1 On Progress in Antibody-Drug Conjugates
10.2.2 On Pharma Strategies for Next-Generation Antibody Therapies
10.2.3 On Competition Between Next-Generation Sectors
10.2.4 On Engineered Antibodies
10.2.5 On Biosimilars
10.2.6 On Next-Generation Antibodies and Personalised Medicine
10.3 Interview with Dr Joanna Horobin, President and CEO, Syndax Pharmaceuticals
10.3.1 On Challenges Facing Cancer Therapies
10.3.2 On Selective Targeting of Therapies
10.3.3 On Drug Resistance and Targeted Therapies
10.3.4 On Drug Resistance and Market Opportunity
10.3.5 On Entinostat, Lung and Breast Cancer Therapies
11. Conclusions
11.1 Top 25 Drugs Dominate the World Anti-Cancer Treatments Market
11.2 Monoclonal Antibodies
11.2.1 Biosimilars have Potential in Emerging Markets
11.3 The US Will Continue to be the Largest Anti-Cancer Drug Market
11.4 India and China Will be the Fastest Growing National Markets
11.5 Personalised Medicine - The Future of Anti-Cancer Therapy
11.6 Anti-Cancer Drug Pipeline is Strong
11.7 Concluding Remarks
List of Tables
Table 2.1 Anti-Cancer Drug Market by Category, 2010
Table 3.1 Global Anti-Cancer Market Sales ($bn) and Market Shares (%) by Category, 2010
Table 3.2 Global Anti-Cancer Market Forecast ($bn), 2010-2012
Table 3.3 Global Anti-Cancer Drug Market: Revenue Forecasts by Category ($bn), 2010-2022
Table 3.4 Global Anti-Cancer Market: Drivers and Restraints, 2012-2022
Table 3.5 Traditional Antineoplastics Market Forecast ($bn), 2010-2022
Table 3.6 Traditional Antineoplastics Market: Drivers and Restraints, 2010-2022
Table 3.7 Novel Antineoplastics Market Forecast ($bn), 2010-2022
Table 3.8 Novel Antineoplastics Market: Drivers and Restraints, 2012-2022
Table 3.9 Hormone Therapy Market Forecast ($bn), 2010-2022
Table 3.10 Hormone Therapy Market: Drivers and Restraints, 2012-2022
Table 3.11 Immunotherapy Market Forecast ($bn), 2010-2022
Table 3.12 Immunotherapy Market: Drivers and Restraints, 2012-2022
Table 4.1 Anti-Cancer Drug Market by Leading Country, 2010
Table 4.2 Developed Markets: Drivers and Restraints, 2010-2022
Table 4.3 Emerging Markets: Drivers and Restraints, 2010-2022
Table 4.4 Global Anti-Cancer Drug Market: Revenue Forecasts by Leading Country ($bn), 2010-2022
Table 4.5 US Anti-Cancer Drug Market Forecast ($bn), 2010-2022
Table 4.6 Japanese Anti-Cancer Drug Market Forecast ($bn), 2010-2022
Table 4.7 The Leading 5 EU Anti-Cancer Drug Markets: Forecasts ($bn), 2010-2022
Table 4.8 BRIC Countries: Anti-Cancer Drug Markets Forecasts ($bn), 2010-2022
Table 5.1 Top 25 Anti-Cancer Drugs: Sales ($bn) and Market Shares (%), 2010
Table 5.2 Top 25 Drugs: Sales Forecasts ($bn), 2010-2022
Table 5.3 Avastin Sales Forecast ($bn), 2010-2022
Table 5.4 Avastin: Sales Drivers and Restraints, 2012-2022
Table 5.5 Rituxan Sales Forecast ($bn), 2010-2022
Table 5.6 Rituxan: Sales Drivers and Restraints, 2012-2022
Table 5.7 Herceptin Sales Forecast ($bn), 2010-2022
Table 5.8 Herceptin: Sales Drivers and Restraints, 2012-2022
Table 5.9 Glivec/Gleevec Sales Forecast ($bn), 2010-2022
Table 5.10 Glivec/Gleevec: Sales Drivers and Restraints, 2012-2022
Table 5.11 Taxotere: Approved Indications, 2010
Table 5.12 Taxotere Sales Forecast ($bn), 2010-2022
Table 5.13 Taxotere: Sales Drivers and Restraints, 2012-2022
Table 5.14 Revlimid Sales Forecast ($bn), 2010-2022
Table 5.15 Revlimid: Sales Drivers and Restraints, 2012-2022
Table 5.16 Alimta Sales Forecast ($bn), 2010-2022
Table 5.17 Alimta: Sales Drivers and Restraints, 2012-2022
Table 5.18 Velcade Sales Forecast ($bn), 2010-2022
Table 5.19 Velcade: Sales Drivers and Restraints, 2012-2022
Table 5.20 Erbitux Sales Forecast ($bn), 2010-2022
Table 5.21 Erbitux: Sales Drivers and Restraints, 2012-2022
Table 5.22 Leuplin Sales Forecast ($bn), 2010-2022
Table 5.23 Arimidex Sales Forecast ($bn), 2010-2022
Table 5.24 Arimidex Sales Drivers and Restraints, 2012-2022
Table 5.25 Zometa Sales Forecast ($bn), 2010-2022
Table 5.26 Xeloda Sales Forecast ($bn), 2010-2022
Table 5.27 Tarceva Sales Forecast ($bn), 2010-2022
Table 5.28 Femara Sales Forecast ($bn), 2010-2022
Table 5.29 Sandostatin Sales Forecast ($bn), 2010-2022
Table 5.30 Gemzar Sales Forecast ($bn), 2010-2022
Table 5.31 Zoladex Sales Forecast ($bn), 2010-2022
Table 5.32 Sutent Sales Forecast ($bn), 2010-2022
Table 5.33 Temodar Sales Forecast ($bn), 2010-2022
Table 5.34 Nexavar Sales Forecast ($bn), 2010-2022
Table 5.35 Casodex Sales Forecast ($bn), 2010-2022
Table 5.36 Sprycel Sales Forecast ($bn), 2010-2022
Table 5.37 Eloxatin Sales Forecast ($bn), 2010-2022
Table 5.38 Vidaza Sales Forecast ($bn), 2010-2022
Table 6.1 Tasigna Sales Forecast ($m), 2010-2022
Table 7.1 Anti-Cancer Drug Sales ($bn) and Market Shares (%) by Leading Company, 2010
Table 7.2 Roche Anti-Cancer Drugs: Sales ($bn), 2010
Table 7.3 Roche Anti-Cancer Drugs: Sales ($bn), 1H 2011
Table 7.4 Selected Drugs from Roche Oncology Pipeline, 2011
Table 7.5 Novartis Anti-Cancer Drugs: Sales ($bn), 2010
Table 7.6 Novartis Anti-Cancer Drugs: Sales ($bn), 2011
Table 7.7 Selected Drugs from Novartis Oncology Pipeline, 2011
Table 7.8 AstraZeneca Anti-Cancer Drugs: Sales ($bn), 2010
Table 7.9 Selected Drugs from AstraZeneca Oncology Pipeline, 2011
Table 7.10 Celgene Anti-Cancer Drugs: Sales ($bn), 2010
Table 7.11 Eli Lilly Anti-Cancer Drugs: Sales ($bn), 2010
Table 7.12 Eli Lilly Anti-Cancer Drugs: Sales ($bn), 2011 (Q1-Q3)
Table 7.13 Selected Drugs from Eli Lilly Oncology Pipeline, 2011
Table 7.14 Sanofi Anti-Cancer Drugs: Sales ($bn), 2010
Table 7.15 Sanofi Anti-Cancer Drugs: Sales ($bn), 1H 2011
Table 7.16 Selected Drugs from Sanofi Oncology Pipeline, 2011
Table 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2011
Table 8.2 Bladder Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.3 Brain Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.4 Breast Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.5 Cervical Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.6 Colorectal Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.7 Kidney Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.8 Leukaemia: Some Late Stage Drugs Under Development, 2011
Table 8.9 Liver Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.10 Lung Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.11 Lymphoma: Some Late Stage Drugs Under Development, 2011
Table 8.12 Multiple Myeloma: Late Stage Drug Under Development, 2011
Table 8.13 Ovarian Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.14 Pancreatic Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.15 Prostate Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.16 Sarcoma: Some Late Stage Drugs Under Development, 2011
Table 8.17 Skin Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.18 Solid Tumours: Some Late Stage Drugs Under Development, 2011
Table 8.19 Stomach Cancer: Some Late Stage Drugs Under Development, 2011
Table 8.20 Other Cancers: Some Late Stage Drugs Under Development, 2011
Table 9.1 SWOT Analysis of the Anti-Cancer Drug Market, 2012-2022
Table 9.2 STEP Analysis of the Anti-Cancer Drug Market, 2012-2022
List of Figures
Figure 3.1 Global Anti-Cancer Market Shares (%) by Category, 2010
Figure 3.2 Global Anti-Cancer Drug Market Forecast ($bn), 2010-2022
Figure 3.3 Global Anti-Cancer Market Shares (%) by Category, 2012
Figure 3.4 Global Anti-Cancer Market Shares (%) by Category, 2022
Figure 3.5 Traditional Antineoplastics Market Forecast ($bn), 2010-2022
Figure 3.6 Novel Antineoplastics Market Forecast ($bn), 2010-2022
Figure 3.7 Hormone Therapy Market Forecast ($bn), 2010-2022
Figure 3.8 Immunotherapy Market Forecast ($bn), 2010-2022
Figure 4.1 Anti-Cancer Drug Market Shares (%) by Leading Country, 2010
Figure 4.2 Anti-Cancer Drug Market Shares (%) by Leading Country, 2015
Figure 4.3 Anti-Cancer Drug Market Shares (%) by Leading Country, 2022
Figure 4.4 US Anti-Cancer Drug Market Forecast ($bn), 2010-2022
Figure 4.5 Japanese Anti-Cancer Drug Market Forecast ($bn), 2010-2022
Figure 4.6 Leading 5 EU Anti-Cancer Drug Market Forecasts ($bn), 2010-2022
Figure 4.7 Brazilian Anti-Cancer Drug Market Forecast ($bn), 2010-2022
Figure 4.8 Russian Anti-Cancer Drug Market Forecast ($bn), 2010-2022
Figure 4.9 Indian Anti-Cancer Drug Market Forecast ($bn), 2010-2022
Figure 4.10 Chinese Anti-Cancer Drug Market Forecast ($bn), 2010-2022
Figure 5.1 Avastin Sales Forecast ($bn), 2010-2022
Figure 5.2 Rituxan Sales Forecast ($bn), 2010-2022
Figure 5.3 Herceptin Sales Forecast ($bn), 2010-2022
Figure 5.4 Glivec/Gleevec Sales Forecast ($bn), 2010-2022
Figure 5.5 Taxotere Sales Forecast ($bn), 2010-2022
Figure 5.6 Revlimid Sales Forecast ($bn), 2010-2022
Figure 5.7 Alimta Sales Forecast ($bn), 2010-2022
Figure 5.8 Velcade Sales Forecast ($bn), 2010-2022
Figure 5.9 Erbitux Sales Forecast ($bn), 2010-2022
Figure 5.10 Leuplin Sales Forecast ($bn), 2010-2022
Figure 5.11 Arimidex Sales Forecast ($bn), 2010-2022
Figure 5.12 Zometa Sales Forecast ($bn), 2010-2022
Figure 5.13 Xeloda Sales Forecast ($bn), 2010-2022
Figure 5.14 Tarceva Sales Forecast ($bn), 2010-2022
Figure 5.15 Femara Sales Forecast ($bn), 2010-2022
Figure 5.16 Sandostatin Sales Forecast ($bn), 2010-2022
Figure 5.17 Gemzar Sales Forecast ($bn), 2010-2022
Figure 5.18 Zoladex Sales Forecast ($bn), 2010-2022
Figure 5.19 Sutent Sales Forecast ($bn), 2010-2022
Figure 5.20 Temodar Sales Forecast ($bn), 2010-2022
Figure 5.21 Nexavar Sales Forecast ($bn), 2010-2022
Figure 5.22 Casodex Sales Forecast ($bn), 2010-2022
Figure 5.23 Sprycel Sales Forecast ($bn), 2010-2022
Figure 5.24 Eloxatin Sales Forecast ($bn), 2010-2022
Figure 5.25 Vidaza Sales Forecast ($bn), 2010-2022
Figure 6.1 Tasigna Sales Forecast ($m), 2010-2022
Figure 7.1 Anti-Cancer Drug Market Shares (%) by Leading Company, 2010
Figure 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2011
Figure 11.1 Top 25 Anti-Cancer Drugs: Sales ($bn), 2010
Figure 11.2 Top 25 Anti-Cancer Drugs: Market Shares (%), 2010
Companies Listed
AB Sciences USA
Abbott Laboratories
Abraxis BioScience
Active Biotech
Advaxis
Aeterna Zentaris
Agenus
Algeta
Allergan
Ambit Biosciences
Amgen
APP Pharmaceuticals
ArQule
Array BioPharma
Astellas Pharma
AstraZeneca
AVEO Pharmaceuticals
Bayer HealthCare
Baylor College of Medicine
BioCancell Therapeutics
Biogen Idec
Bioniche Life Sciences
BioVEX
BiPar Sciences
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Cancer Advances
Celgene
Celldex Therapeutics
Chugai
Cipla
Cougar Biotechnology
Cyclacel Pharmaceuticals
Daiichi Sankyo
Dako
Dan L. Duncan Cancer Center
Dendreon
Dr. Reddy's Laboratories
Eisai
Eleison Pharmaceuticals
Eli Lilly
EMD Serono
Endo Pharmaceuticals
European Medicines Agency (EMA)
Exelixis
Food and Drug Administration (US FDA)
GE Healthcare
Genentech
GenMab
Genta
Genzyme
GlaxoSmithKline (GSK)
Hospira
ImClone Systems
Inovio Pharmaceuticals
International Cancer Genome Consortium
Janssen-Cilag
Johnson & Johnson (J&J)
Keryx Biopharmaceuticals
Lester and Sue Smith Breast Center, Baylor College of Medicine
Lpath
Marshall Edwards
MedImmune
Medivation
Menarini
Merck & Co.
Merck Serono
Micromet
Millennium Pharmaceuticals
Mylan
National Health Service (UK)
National Institute for Health and Clinical Excellence (NICE, UK)
Nektar Therapeutics
Novartis
OncoGenex Pharmaceuticals
Onconova Therapeutics
Onyx Pharmaceuticals
OSI Pharmaceuticals
Otsuka
Oxford University
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Plexxikon
Progen Pharmaceuticals
Proteolix
Puma Biotechnology
Radient
RBC Capital Markets
Regeneron
Roche
Sandoz
Sanofi
Seattle Genetics
Spectrum Pharmaceuticals
Sunesis Pharmaceuticals
Syndax Pharmaceuticals
Tactic Pharma
Taiho Pharma USA
Takeda
TargeGen
TenX Biopharma
Teva Pharmaceutical Industries
Transgene
UCB
United Therapeutics
Vaccine Company
Wellstat Biologics
Wilex
World Health Organization (WHO)
Yaupon Therapeutics
Zenyaku Kogyo
ZIOPHARM Oncology
Zor Pharmaceuticals
To order this report:
Drug and Medication Industry: Leading Anti-Cancer Drugs and Associated Market 2012-2022
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article